JP6466500B2 - 多価rna−ナノ粒子組成物 - Google Patents
多価rna−ナノ粒子組成物 Download PDFInfo
- Publication number
- JP6466500B2 JP6466500B2 JP2017082667A JP2017082667A JP6466500B2 JP 6466500 B2 JP6466500 B2 JP 6466500B2 JP 2017082667 A JP2017082667 A JP 2017082667A JP 2017082667 A JP2017082667 A JP 2017082667A JP 6466500 B2 JP6466500 B2 JP 6466500B2
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- rna
- nanoparticle
- nanoparticle composition
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims description 349
- 239000000203 mixture Substances 0.000 title claims description 135
- 102000040430 polynucleotide Human genes 0.000 claims description 252
- 108091033319 polynucleotide Proteins 0.000 claims description 252
- 239000002157 polynucleotide Substances 0.000 claims description 251
- 229920002477 rna polymer Polymers 0.000 claims description 190
- 239000002773 nucleotide Substances 0.000 claims description 64
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 239000010931 gold Substances 0.000 claims description 49
- 229920001184 polypeptide Polymers 0.000 claims description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 230000000295 complement effect Effects 0.000 claims description 33
- 239000000758 substrate Substances 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 25
- 238000009396 hybridization Methods 0.000 claims description 24
- 230000003993 interaction Effects 0.000 claims description 23
- 108020004414 DNA Proteins 0.000 claims description 22
- 102000053602 DNA Human genes 0.000 claims description 22
- 108010057163 Ribonuclease III Proteins 0.000 claims description 22
- 102000003661 Ribonuclease III Human genes 0.000 claims description 22
- 229910052737 gold Inorganic materials 0.000 claims description 22
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 20
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 claims description 17
- 102100023387 Endoribonuclease Dicer Human genes 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 102100034343 Integrase Human genes 0.000 claims description 8
- 101710203526 Integrase Proteins 0.000 claims description 8
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 claims description 7
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 6
- 101710159080 Aconitate hydratase A Proteins 0.000 claims description 3
- 101710159078 Aconitate hydratase B Proteins 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 102000044126 RNA-Binding Proteins Human genes 0.000 claims description 3
- 101710105008 RNA-binding protein Proteins 0.000 claims description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 description 60
- 108091034117 Oligonucleotide Proteins 0.000 description 56
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 48
- 235000002639 sodium chloride Nutrition 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 36
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 31
- 102000039446 nucleic acids Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 150000007523 nucleic acids Chemical class 0.000 description 29
- 125000006850 spacer group Chemical group 0.000 description 25
- 239000011780 sodium chloride Substances 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 230000000692 anti-sense effect Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 239000002245 particle Substances 0.000 description 19
- -1 magnetic properties Substances 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 18
- 102000006382 Ribonucleases Human genes 0.000 description 17
- 108010083644 Ribonucleases Proteins 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 17
- 230000032683 aging Effects 0.000 description 15
- 230000027455 binding Effects 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- 230000009368 gene silencing by RNA Effects 0.000 description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 10
- 108091081021 Sense strand Proteins 0.000 description 10
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000004055 small Interfering RNA Substances 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000012266 salt solution Substances 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 6
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 6
- 229940104302 cytosine Drugs 0.000 description 6
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000007306 functionalization reaction Methods 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 108090000331 Firefly luciferases Proteins 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 125000004437 phosphorous atom Chemical group 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 4
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical class O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000006916 protein interaction Effects 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000005070 ripening Effects 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 2
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 2
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 241000242739 Renilla Species 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000003705 background correction Methods 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 238000002161 passivation Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 230000011273 social behavior Effects 0.000 description 2
- 125000002345 steroid group Chemical group 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 239000005450 thionucleoside Substances 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- UFSCXDAOCAIFOG-UHFFFAOYSA-N 1,10-dihydropyrimido[5,4-b][1,4]benzothiazin-2-one Chemical compound S1C2=CC=CC=C2N=C2C1=CNC(=O)N2 UFSCXDAOCAIFOG-UHFFFAOYSA-N 0.000 description 1
- PTFYZDMJTFMPQW-UHFFFAOYSA-N 1,10-dihydropyrimido[5,4-b][1,4]benzoxazin-2-one Chemical compound O1C2=CC=CC=C2N=C2C1=CNC(=O)N2 PTFYZDMJTFMPQW-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- HASUWNAFLUMMFI-UHFFFAOYSA-N 1,7-dihydropyrrolo[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)NC2=C1C=CN2 HASUWNAFLUMMFI-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- WKMPTBDYDNUJLF-UHFFFAOYSA-N 2-fluoroadenine Chemical compound NC1=NC(F)=NC2=C1N=CN2 WKMPTBDYDNUJLF-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- PDBUTMYDZLUVCP-UHFFFAOYSA-N 3,4-dihydro-1,4-benzoxazin-2-one Chemical compound C1=CC=C2OC(=O)CNC2=C1 PDBUTMYDZLUVCP-UHFFFAOYSA-N 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- PLUDYDNNASPOEE-UHFFFAOYSA-N 6-(aziridin-1-yl)-1h-pyrimidin-2-one Chemical compound C1=CNC(=O)N=C1N1CC1 PLUDYDNNASPOEE-UHFFFAOYSA-N 0.000 description 1
- SXQMWXNOYLLRBY-UHFFFAOYSA-N 6-(methylamino)purin-8-one Chemical compound CNC1=NC=NC2=NC(=O)N=C12 SXQMWXNOYLLRBY-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- NJBMMMJOXRZENQ-UHFFFAOYSA-N 6H-pyrrolo[2,3-f]quinoline Chemical compound c1cc2ccc3[nH]cccc3c2n1 NJBMMMJOXRZENQ-UHFFFAOYSA-N 0.000 description 1
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001362614 Crassa Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 102000047781 Ribonuclease H domains Human genes 0.000 description 1
- 108700037838 Ribonuclease H domains Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000001369 canonical nucleoside group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 150000004662 dithiols Chemical group 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 101150076185 mut-7 gene Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 150000002991 phenoxazines Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000005240 physical vapour deposition Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- RXTQGIIIYVEHBN-UHFFFAOYSA-N pyrimido[4,5-b]indol-2-one Chemical compound C1=CC=CC2=NC3=NC(=O)N=CC3=C21 RXTQGIIIYVEHBN-UHFFFAOYSA-N 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- SRBUGYKMBLUTIS-UHFFFAOYSA-N pyrrolo[2,3-d]pyrimidin-2-one Chemical compound O=C1N=CC2=CC=NC2=N1 SRBUGYKMBLUTIS-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ceramic Engineering (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
Description
本発明は、National Cancer Institute/Centers of Cancer Nanotechnology Excellence(NCI/CCNE)によって付与された助成金第5U54 CA119341号、およびにNational Institutes of Health(NIH)よって付与された助成金第5DP1 OD000285号の下、政府の支援を受けてなされた。政府は、本発明に一定の権利を有する。
本発明は、二重鎖RNAを用いて機能化されたナノ粒子に関する。本発明はまた、RNAをナノ粒子に結合体化させる方法を提供する。
NP)を設計、合成、試験、および利用してきた[Mirkinら、「Nature」382:607(1996)]。こうした努力によって、ハイブリッドナノ構造についての新規の基本理解[Demersら、「Anal.Chem.」72:5535(2000);Jinら、「J.Am.Chem.Soc.」125:1643(2003);Lytton−Jeanら、「J.Am.Chem Soc」127:12754〜12754(2005);Storhoffら、「J.Am.Chem.Soc.」122:4640(2000);Youら、「Soft Matter」2:190(2006);Wangら、「Nanomed.」1:413(2006)]、重要でありかつ場合によっては商業的に実現可能である検出および診断アッセイ[Namら、「Science」301:1884(2003);Stoevaら、「J.Am.Chem.Soc.」128:8378(2006);Liuら、「J.Am.Chem.Soc.」126:12298(2004);Fauldsら、「Anal.Chem.」76:412(2004)]、およびDNAシントンの使用を介する材料組立をプログラムする能力[Mirkinら、「Nature」382:607(1996);Parkら、「Nature」451:553(2008);Nykypanchukら、「Nature」451:549(2008)]が得られてきた。多価DNA−Au NPには、融解温度の尖鋭化および上昇[Jinら、「J.Am.Chem.Soc.」125:1643(2003)]、結合特性の向上[Lytton−Jeanら、「J.Am.Chem Soc」127:12754−12754(2005)](同配列の遊離鎖と比較した場合)、および距離依存性光学特性[Elghanianら、「Science」277:1078(1997)]などのいくつかの独特な特性がある。多価分子系に関する研究[Gestwickiら、「J.Am.Chem.Soc.」124:14922(2002)]に同意するならば、ナノ粒子の、高い表面DNA密度や、多座配位相互作用に関わる能力が、こうした独特な特性の由来を提示するものである。
(a)約0.1M塩化ナトリウム(NaCl)を含む溶液中で、チオール化RNA二重鎖をナノ粒子と混合すること;
(b)先の溶液よりも増大した濃度のNaClをそれぞれ含む一連の塩溶液中で、混合物を熟成させること;
(c)混合物を超音波処理すること;および
(d)結合体化されたナノ粒子を調製すること。
多価粒子およびその並外れた特性を利用して、RNAを装填し、細胞膜を通過させるための方法は、今日まで開発されてこなかった。RNAに関する最も難しい問題の1つ、すなわち特にその化学的不安定性を克服する合成の経路および材料が開発される必要が、確かに存在する。
したがって、ポリヌクレオチドを付着させるために機能化されたナノ粒子が提供される。ナノ粒子のサイズ、形状、および化学組成は、得られるポリヌクレオチドで機能化されたナノ粒子の特性に寄与する。これらの特性には、例えば、光学特性、光電子特性、電気化学特性、電子特性、様々な溶液中での安定性、磁気特性、および細孔やチャネルのサイズの変動が含まれる。サイズ、形状、および/または化学組成が様々であるナノ粒子の混合物、ならびにサイズ、形状、および化学組成が一様であるナノ粒子、ひいてはこれらの特性の混合物の使用が企図される。適切な粒子の例としては、限定されないが、凝集粒子、等方性粒子(球状粒子など)、異方性粒子(非球状の棒状体、四面体、および/または角柱など)、およびコアシェル粒子(その開示全体が参照により組み込まれる米国特許第7,238,472号および国際公開第WO2003/08539号に記載されているものなど)が挙げられる。
したがって、二重鎖RNAがナノ粒子と結合するような、ポリヌクレオチドが付着されたナノ粒子が提供される。ある態様では、ナノ粒子と結合するRNAは、低分子干渉RNA(siRNA)である。二重鎖RNAとナノ粒子との様々な手段を介した結びつきが企図される。
センス 対 アンチセンス
ある態様では、ナノ粒子に付着されるRNAの鎖は、「センス」鎖であり、二重鎖RNAの相補鎖は、センス鎖とはハイブリッド形成するが、ナノ粒子には付着しない。他の態様では、ナノ粒子に付着されるRNAの鎖は、「アンチセンス」鎖であり、二重鎖RNAの相補鎖は、アンチセンス鎖とはハイブリッド形成するが、ナノ粒子には付着しない。本明細書で使用する場合、「センス」鎖は、標的ポリヌクレオチドと同一の鎖であり、「アンチセンス」鎖は、標的ポリヌクレオチドと相補的な鎖である。センス鎖またはアンチセンス鎖のナノ粒子への付着によって、二本鎖RNAのナノ粒子に対する方向性の一態様が決定される。
ある実施形態では、ナノ粒子に付着されるポリヌクレオチドがRNAであることが、本開示によって企図される。また、RNA内の配列に位置するタンパク質相互作用部位がナノ粒子に対して近くまたは遠くになるように、ポリヌクレオチドがナノ粒子に付着されることも企図される。これらの態様では、「近く」および「遠く」は、ポリヌクレオチド上の中間点を指す。例えば、ナノ粒子に付着するポリヌクレオチドの長さが20塩基であれば、その中間点は、ナノ粒子から10塩基の位置になり、タンパク質相互作用部位は、この第10塩基に対して近くまたは遠くであり得る。
ある種の態様では、オリゴヌクレオチドがスペーサーを介してナノ粒子に付着するものを含めた、機能化されたナノ粒子が企図される。本明細書で使用する場合、「スペーサー」は、それ自体は遺伝子発現の調節に関与しないが、ナノ粒子と機能性オリゴヌクレオチドとの間の距離を広げるのに、または多重コピーでナノ粒子に付着する場合には個々のオリゴヌクレオチド間の距離を広げるのに役立つ部分を意味する。したがって、スペーサーは、オリゴヌクレオチドが同一の配列を有するとしても異なる配列を有するとしても、個々のオリゴヌクレオチド間に並べて配置されることが企図される。一態様では、スペーサーは、存在する場合、有機部分である。別の態様では、スペーサーは、これに限定されないが水溶性ポリマーを含めたポリマーや、核酸、ポリペプチド、オリゴ糖、炭水化物、脂質、エチルグリコール、またはこれらの組み合わせである。
本明細書で提供するナノ粒子は、ナノ粒子間および単一ナノ粒子上のポリヌクレオチド鎖間の協同的挙動をもたらすのに、種々の態様において十分であるような、ポリヌクレオチドのナノ粒子表面上での充填密度を有する。別の態様では、ナノ粒子間の協同的挙動によって、ヌクレアーゼ分解に対するポリヌクレオチドの耐性が増大する。さらに別の態様では、細胞によるナノ粒子の取り込みは、ナノ粒子と結合するポリヌクレオチドの密度によって影響される。参照により本明細書にその全体が組み込まれるPCT/US2008/65366に記載の通り、ナノ粒子の表面上のポリヌクレオチドの密度がより高いことは、細胞によるナノ粒子の取り込みの増大と関連する。
本方法に使用を企図されるポリヌクレオチドとしては、任意の手段を介してナノ粒子に結合されるポリヌクレオチドが挙げられる。ポリヌクレオチドをナノ粒子に付着させる手段にかかわらず、種々の態様における付着は、5’連結、3’連結、ある種類の内部連結、またはこれらの付着の任意の組み合わせを介して行われる。
本明細書で使用する場合、用語「ヌクレオチド」またはその複数形は、本明細書で論じる通りの改変された形や、その他当分野で既知のものと同義的である。ある種の例では、当分野では、天然に存在するヌクレオチド、ならびに重合可能なヌクレオチドの改変形態を包含する、用語「核酸塩基」が使用される。したがって、ヌクレオチドまたは核酸塩基は、天然に存在する核酸塩基、すなわちアデニン(A)、グアニン(G)、シトシン(C)、チミン(T)、ウラシル(U)、ならびに天然に存在しない核酸塩基、すなわちキサンチン、ジアミノプリン、8−オキソ−N6−メチルアデニン、7−デアザキサンチン、7−デアザグアニン、N4,N4−エタノシトシン、N’,N’−エタノ−2,6−ジアミノプリン、5−メチルシトシン(mC)、5−(C3〜C6)−アルキニル−シトシン、5−フルオロウラシル、5−ブロモウラシル、プソイドイソシトシン、2−ヒロドキシ−5−メチル−4−トリアゾロピリジン、イソシトシン、イソグアニン、イノシン、ならびに、Bennerら、米国特許第5,432,272号およびSusan M.FreierおよびKarl−Heinz Altmann、1997、「Nucleic Acids Research」、第25巻:4429〜4443頁に記載されている「天然に存在しない」核酸塩基、を意味する。用語「核酸塩基」には、既知のプリン複素環およびピリジン複素環だけでなく、それらの複素環式類似体および互変異性体も含まれる。さらに、天然に存在するおよび天然に存在しない核酸塩基としては、参照により本明細書にそれぞれその全体が組み込まれる、米国特許第3,687,808号(Meriganら)に;「Antisense Research and Application」、S.T.CrookeおよびB.Lebleu編、CRC Press、1993中の、SanghviによるChapter 15に;Englischら、1991、「Angewandte Chemie,International Edition」、30:613〜722(特に622頁および623頁参照)に;また、「the Concise Encyclopedia of Polymer Science and Engineering」、J.I.Kroschwitz編、John Wiley&Sons、1990、858〜859頁、Cook、「Anti−Cancer Drug Design 1991」、6、585〜607に開示されているものも挙げられる。種々の態様では、ポリヌクレオチドは、最も典型的な意味ではヌクレオシド塩基ではないが、ヌクレオシド塩基として機能する、ある種の「万能塩基」を含めて、核酸塩基のように機能することができる複素環式化合物などの化合物を含めた1種または複数の「ヌクレオシド塩基」または「塩基単位」も含む。万能塩基としては、3−ニトロピロール、任意選択で置換されたインドール(例えば、5−ニトロインドール)、および任意選択で置換されたヒポキサンチンが挙げられる。他の望ましい万能塩基としては、当分野で既知の万能塩基を含めた、ピロール誘導体、ジアゾール誘導体、またはトリアゾール誘導体が挙げられる。
本開示は、種々の実施形態において、遺伝子調節に有用である多価RNA−ナノ粒子組成物を提供する。低分子干渉RNAは、標的RNA(一般にメッセンジャーRNA(mRNA))の一部との相補性を有する(すなわちハイブリッド形成できる)二本鎖RNA因子である。こうした相補性は、一般には、100%であるが、所望により、例えば、約20%、約25%、約30%、約35%、約40%、約45%、約50%、約55%、約60%、約70%、約75%、76%、77%、78%、79%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%のように低くすることができる。例えば、21塩基のうちの19塩基を塩基対合させることができる。したがって、本方法において使用されるオリゴヌクレオチドは、特異的にハイブリッド形成可能であるために、所望の標的核酸と100%相補的である必要はないことが理解されるであろう。さらに、オリゴヌクレオチドは、介在または隣接セグメントがハイブリッド形成事象(例えば、ループ構造またはヘアピン構造)に関与しないように、1つまたは複数のセグメントを飛び越えて互いにハイブリッド形成することができる。任意の所与のオリゴヌクレオチド間の相補性(%)は、当分野で既知のBLAST(Basic Local Alignment Search Tools)プログラムおよびPowerBLASTプログラムを使用して、機械的に決定することができる(Altschulら、1990、「J.Mol.Biol.」、215:403〜410;ZhangおよびMadden、1997、「Genome Res.」、7:649〜656)。
ある態様では、本開示は、特定の核酸を標的にする方法を提供する。いかなる種類の核酸も標的にすることができ、本方法は、例えば、遺伝子発現の治療的調節のために使用することができる(例えば、その開示が参照により本明細書に組み込まれるPCT/US2006/022325を参照されたい)。本発明の方法により標的にされる核酸の例としては、遺伝子(例えば、特定の疾患に関連する遺伝子)、ウイルスRNA、またはmRNA、RNA、一本鎖の核酸が挙げられるが、これに限定されない。
ナノ粒子を機能化させるために、ポリヌクレオチド中のヌクレオチド単位の1つまたは複数の糖かつ/または1つまたは複数のヌクレオチド間連結が、「天然に存在しない」基で置き換えられるような、改変されたポリヌクレオチドが企図される。一態様では、この実施形態は、ペプチド核酸(PNA)を企図する。PNA化合物において、ポリヌクレオチドの糖骨格は、アミド含有骨格で置き換えられる。例えば、その開示が参照により本明細書に組み込まれる、米国特許第5,539,082号;第5,714,331号;および第5,719,262号、およびNielsenら、「Science」、1991、254、1497〜1500を参照されたい。
所与の化合物中のすべての位置が一様に改変される必要はなく、実際には、2つ以上の上述の改変が、単一の化合物中に組み込まれても、あるオリゴヌクレオチド内の単一のヌクレオシドに組み込まれてもよい。こうした「キメラ」アンチセンス化合物は、典型的には、本明細書に記述する通りの改変形態を含む少なくとも1つの領域を含有するが、残りのオリゴヌクレオチドは「未改変」のままである。
RNaseを含まないナノ粒子の調製
クエン酸で安定化された金ナノ粒子(13nm)を、発表されている手順[Frens、Nature Physical Science 241:20〜22(1973)]を使用して調製した。合成後、粒子を0.1%ジエチルピロカーボネート(DEPC)で、攪拌しながら12時間処理し、次いで、121℃で60分間オートクレーブした。重要なことに、また、かなり驚いたことに、紫外分光および透過型電子顕微鏡TEM分析(図1)によって測定された通り、このナノ粒子の光学的および物理的特性は、この比較的過酷な処理によって影響を受けない。それに続くリガンド官能化も、この処理によって影響を受けなかった。RNase Alertキット(Ambion)を使用して、これらの溶液のRNase活性を試験しても、対照または未処理粒子(図2)と比較して、検出可能なRNase活性は示されなかった。
RNaseを含まないナノ粒子の改変
RNaseを含まない得られたナノ粒子は、発表されている方法[Demersら、Anal.Chem.72:5535(2000)]を使用する、チオール化オリゴヌクレオチドによるさらなる改変に適用可能であった。この前処理を行わないと、おそらく、RNAベースの表面を覆うリガンドの急速な分解によって、RNAを用いるそれに続く機能化は達成できなかった。27塩基のRNA鎖と、エチレングリコールスペーサーおよびアルキルチオールを末端とする25塩基の相補鎖とからなる二重鎖をハイブリッド形成させ、チオール−金結合を介して化学吸着が可能となるような、RNaseを含まないAu NPに付加した。この研究のために、これらの配列は、ホタルルシフェラーゼ遺伝子を標的とするように設計された。
RNA−ナノ粒子組成物の細胞内取り込み
組成物が細胞に入る能力を、上述の通りに調製した蛍光(シアニン5、Cy5)組成物を使用して、共焦点顕微鏡によって調べた。RNA−Au NPをHeLa細胞の培養物に添加した。細胞をガラスカバーガラス上で生育させ、蛍光標識したRNA二重鎖で機能化されたナノ粒子で処理した。処理の6時間後、このカバーガラスを取り除き、PBSで洗浄し、スライドガラス上に装備した、PBSを満たしたチャンバーに固定した。画像はすべて、63×の拡大率と633nm HeNeレーザー励起源で、走査型共焦点顕微鏡(Zeiss 510 LSM)よって取得した。画像研究によれば、6時間後のHeLa細胞の細胞質中のいたるところに、蛍光が現れる(図4a)。興味深いことに、DNA Au−NPのように、RNA Au−NPは、細胞に入るために形質移入剤を必要としない[Giljohannら,Nano Lett.7:3818(2007)]。実際、分析的フローサイトメトリーによって、細胞集団の99%より多くでRNA−Au NPの取り込みが確認された(図4b)。このフローサイトメトリー実験のために、細胞を、蛍光標識された(Cy5)RNA−ナノ粒子組成物で処理した。形質移入の6時間後に細胞をトリプシン処理して、細胞培養ウェルから細胞を取り出した。フローサイトメトリーは、励起635nmでDakoCytomation CyAnを使用して行った。
RNA−ナノ粒子組成物の活性
RNA−Au NPが細胞によって内部に取り込まれたことが確定したので、次に、RNA−金ナノ粒子組成物の細胞内活性を試験した。このモデル系の標的として、形質移入されたルシフェラーゼプラスミドを使用して、タンパク質ノックダウン研究をHeLa細胞で行った。HeLa細胞(ATCC)を、10%の熱失活したウシ胎仔血清(FBS)を含むEagleの最少基本培地(EMEM)中で生育させ、5%CO2中で37℃で維持した。細胞を96ウェルプレートに播種し、1日生育させて、ホタルルシフェラーゼとウミシイタケ遺伝子の両方を含有するプラスミド(psiCHECK2、Promega)を形質移入した。プラスミド(ウェルあたり0.2μg)を、製造者の勧告に従ってLipofectamine2000(Invitrogen)を使用して加えた。プラスミド導入後(24時間)、培地を、ホタルルシフェラーゼに指向する機能化されたRNA−Au NP(3nMナノ粒子濃度、約100nM RNA二重鎖濃度)を含有する低血清培地に交換した。処理の1日目には、細胞は約70%集密であった。実験の終わりに、処理された細胞の反復実験ウェルを、Guava EasyCyte Mini(Guava Technologies)を使用して、生存率について計数および測定した。インキュベーション後の生存率は、RNA Au NPで処理した細胞については98%を超えていた。
ology International FluoDia T70蛍光プレートリーダー中に配置した。このサンプルを平衡化(10分)させた後、10μLのウシ胎仔血清(FBS、Gemini Bioproducts)を加えて、サンプルを10%の血清濃度にした。蒸発を防止するために、この反応物を40μLの鉱油で覆った。サンプルの蛍光(励起=530nm、発光=570nm)を5分毎に48時間測定した。ベースラインの蛍光は、FBSの代わりに10μL分量のPBSで処理したサンプルから決定した。反応の終点は、時間の関数として観察される蛍光がさらに増加しなくなった時点に決定した。すべてのサンプルを3回測定した。
ナノ粒子表面上のポリヌクレオチドの方向性
ナノ粒子上に固定化されるRNAの方向性は、制御可能である。Dicer酵素に対するRNA基質を固定化する戦略によって、二本鎖への接近の制御が可能になる。様々な固定化化学、モノチオールまたはジチオール、および様々な長さのスペーサー配列を利用して、RNA二本鎖の数およびRNA二本鎖間の距離を変動させることによって、RNA分解の速度を制御することができる。
本発明は以下をも提供する。
(1)ナノ粒子と結合した1つまたは複数のリボ核酸(RNA)ポリヌクレオチドを含むナノ粒子組成物であって、
該RNAポリヌクレオチドが、ポリペプチドの相互作用部位を有し;
該RNAポリヌクレオチドが、二重鎖を形成するのに適した条件下で該二重鎖を形成する配列を有し;
該二重鎖は、該二重鎖の一本鎖内に、該一本鎖と標的ポリヌクレオチドとのハイブリッド形成を適切な条件下で可能にする、該標的ポリヌクレオチド内の配列と十分に相補的な少なくとも1つのドメインを有し、該二重鎖の該ドメインと該標的ポリヌクレオチド内の該配列とのハイブリッド形成によって、ポリペプチドによって認識される基質部位がもたらされ;
該RNAポリヌクレオチドが、該ポリペプチドの相互作用部位および該ナノ粒子に対して方向特異的な様式で該ナノ粒子と結合する;
ナノ粒子組成物。
(2)前記RNAポリヌクレオチドが、前記ナノ粒子と共有結合している、項目1に記載のナノ粒子組成物。
(3)前記RNAポリヌクレオチドが、前記ナノ粒子と共有結合していない、項目1に記載のナノ粒子組成物。
(4)前記ナノ粒子と結合した各RNAポリヌクレオチドが、同一の配列を有する、項目1に記載のナノ粒子組成物。
(5)前記ナノ粒子と結合した少なくとも2つのRNAポリヌクレオチドが、異なる配列を有する、項目1に記載のナノ粒子組成物。
(6)前記二重鎖が、前記RNAポリヌクレオチドによって形成されたヘアピン構造を含む、項目1に記載のナノ粒子組成物。
(7)前記二重鎖を形成するのに適した条件下で前記RNAポリヌクレオチドとのハイブリッド形成を可能にするための、該RNAポリヌクレオチド内の配列と十分に相補的な配列を有する追加のポリヌクレオチドをさらに含む、項目1に記載のナノ粒子組成物。
(8)前記追加のポリヌクレオチドがRNAである、項目7に記載のナノ粒子組成物。
(9)前記追加のポリヌクレオチドがデオキシリボ核酸(DNA)である、項目7に記載のナノ粒子組成物。
(10)前記追加のポリヌクレオチドが前記ナノ粒子と共有結合している、項目7に記載のナノ粒子組成物。
(11)前記追加のポリヌクレオチドが前記ナノ粒子と共有結合していない、項目7に記載のナノ粒子組成物。
(12)前記ポリペプチドの相互作用部位が、前記RNAポリヌクレオチドの中間点に関して、前記ナノ粒子に対して近位に位置する、項目1に記載のナノ粒子組成物。
(13)前記ポリペプチドの相互作用部位が、前記RNAポリヌクレオチドの中間点に関して、前記ナノ粒子に対して遠位に位置する、項目1に記載のナノ粒子組成物。
(14)前記RNAの表面密度が、少なくとも約2pmol/cm2から約1000pmol/cm2である、項目1に記載のナノ粒子組成物。
(15)前記ポリペプチドの相互作用部位が、RNaseH、RNaseD、RNaseL、RNaseIII、Dicer、Argonaute、Argonaute2、およびヒト免疫不全ウイルスのトランス活性化応答RNA結合タンパク質(TRBP)からなる群より選択されるタンパク質と結合する、項目1に記載のナノ粒子組成物。
(16)前記ポリヌクレオチドの前記ドメインの長さが、約10ヌクレオチドである、項目1に記載のナノ粒子組成物。
(17)前記RNAポリヌクレオチドが、前記標的ポリヌクレオチド内の第2の配列と十分に相補的な第2のドメインをさらに含み、該RNAポリヌクレオチドの該第2のドメインと該標的ポリヌクレオチド内の該第2の配列とのハイブリッド形成によって、第2のポリペプチドによって認識される追加の基質部位がもたらされる、項目16に記載のナノ粒子組成物。
(18)前記ポリヌクレオチドの前記第2のドメインの長さが、約10ヌクレオチドである、項目17に記載のナノ粒子組成物。
(19)前記基質部位と前記追加の基質部位が同じである、項目17に記載のナノ粒子組成物。
(20)前記基質部位と前記追加の基質部位が異なる、項目17に記載のナノ粒子組成物。
(21)前記RNAポリヌクレオチドと前記追加のポリヌクレオチドが、ハイブリッド形成できるのに十分な長さにわたって互いに相補的である、項目7に記載のナノ粒子組成物。
(22)前記RNAポリヌクレオチドと前記追加のポリヌクレオチドが、それらの全長にわたって互いに相補的である、項目21に記載のナノ粒子組成物。
(23)前記RNAポリヌクレオチドが、チオール連結を介して前記ナノ粒子と結合体化される、項目1に記載のナノ粒子組成物。
(24)前記RNAポリヌクレオチドの半減期が、ナノ粒子と結合していない同一のRNAポリヌクレオチドの半減期と少なくとも実質的に同じである、項目1に記載のナノ粒子組成物。
(25)前記RNAポリヌクレオチドの半減期が、ナノ粒子と結合していない同一のRNAポリヌクレオチドの半減期よりも約1倍以上、約2倍以上、約3倍以上、約4倍以上、約5倍以上長い、項目1に記載のナノ粒子組成物。
(26)前記RNAポリヌクレオチドの長さが、約5から約100ヌクレオチドである、項目1に記載のナノ粒子組成物。
(27)前記追加のポリヌクレオチドの長さが、約5から約100ヌクレオチドである、項目7に記載のナノ粒子組成物。
(28)金ナノ粒子である項目1に記載のナノ粒子組成物。
(29)銀ナノ粒子である項目1に記載のナノ粒子組成物。
(30)RNAポリヌクレオチドをナノ粒子に結合させる方法であって、チオール化RNAポリヌクレオチド二重鎖と該ナノ粒子との混合物を一連の溶液中で熟成させて、該RNAポリヌクレオチドを該ナノ粒子に結合させるステップを含み、各溶液は、約0.1M NaClを含む第1の溶液から開始して、先の溶液よりも増大した濃度の塩化ナトリウム(NaCl)を含む、方法。
(31)最後の前記熟成ステップの後に、前記混合物を超音波処理するステップをさらに含む、項目30に記載の方法。
(32)前記ナノ粒子を単離するステップをさらに含む、項目30または31に記載の方法。
(33)RNAをナノ粒子に結合させる方法であって、
(a)約0.1M塩化ナトリウム(NaCl)を含む溶液中で、チオール化RNA二重鎖を該ナノ粒子と混合すること;
(b)先の溶液よりも増大した濃度のNaClをそれぞれ含む一連の塩溶液中で、該混合物を熟成させること;
(c)該混合物を超音波処理すること;および
(d)結合体化された該ナノ粒子を精製すること
を含む方法。
(34)前記一連の塩溶液が、約0.1Mから約0.3M NaClの範囲である、項目33に記載の方法。
(35)オリゴ(エチレングリコール)チオール(OEG)を用いて前記ナノ粒子の表面を不動態化することをさらに含む、項目33に記載の方法。
(36)標的ポリヌクレオチドの発現を調節する方法であって、項目1に記載のナノ粒子組成物のドメインと該標的ポリヌクレオチドをハイブリッド形成させて、ポリペプチドのための基質部位を形成させるステップを含む、方法。
(37)ハイブリッド形成によって前記標的ポリヌクレオチドの分解をもたらす、項目36に記載の方法。
(38)前記ポリペプチドが、RNaseH、RNaseD、RNaseL、RNaseIII、Dicer、Argonaute、Argonaute2、およびTRBPからなる群より選択される、項目37に記載の方法。
Claims (23)
- ナノ粒子と結合したリボ核酸(RNA)ポリヌクレオチドを含むナノ粒子組成物であって、
該RNAポリヌクレオチドが、該ナノ粒子と官能化されており、標的ポリヌクレオチドと同一の配列を含み;
該RNAポリヌクレオチドが、追加のポリヌクレオチドとともに二重鎖を形成するのに適した条件下で該二重鎖を形成する配列を有し、該追加のポリヌクレオチドは、該二重鎖を形成するのに適切な条件で該RNAポリヌクレオチドに対するハイブリッド形成を可能にするために該RNAポリヌクレオチドにおける配列に十分に相補的な配列を有し、該二重鎖はポリペプチドの相互作用部位を提供し;
該追加のポリヌクレオチドは、該追加のポリヌクレオチドと標的ポリヌクレオチドとのハイブリッド形成を適切な条件下で可能にする、該標的ポリヌクレオチド内の配列と十分に相補的であり、長さが10〜30ヌクレオチドである少なくとも1つのドメインを有し、該追加のポリヌクレオチドの該ドメインと該標的ポリヌクレオチドとのハイブリッド形成によって、ポリペプチドによって認識される基質部位がもたらされ;
該RNAポリヌクレオチドが、該ポリペプチドの相互作用部位および該ナノ粒子に対して方向特異的な様式で該ナノ粒子と結合し、ここで、該RNAポリヌクレオチドを該ナノ粒子に結合させるために、該ナノ粒子、該RNAポリヌクレオチドまたはその両方が官能化されている;
ナノ粒子組成物。 - 前記RNAポリヌクレオチドが、前記ナノ粒子と共有結合している、請求項1に記載のナノ粒子組成物。
- 前記ナノ粒子は、少なくとも2つのRNAポリヌクレオチドを含み、該ナノ粒子と結合した各RNAポリヌクレオチドが、同一の配列を有する、請求項1に記載のナノ粒子組成物。
- 前記追加のポリヌクレオチドがRNAである、請求項1に記載のナノ粒子組成物。
- 前記追加のポリヌクレオチドがデオキシリボ核酸(DNA)である、請求項1に記載のナノ粒子組成物。
- 前記追加のポリヌクレオチドが前記ナノ粒子と共有結合していない、請求項1に記載のナノ粒子組成物。
- 前記ポリペプチドの相互作用部位が、前記RNAポリヌクレオチドの中間点に関して、前記ナノ粒子に対して遠位に位置する、請求項1に記載のナノ粒子組成物。
- 前記RNAの表面密度が、少なくとも2pmol/cm2である、請求項1に記載のナノ粒子組成物。
- 前記ポリペプチドの相互作用部位が、RNaseH、RNaseD、RNaseL、RNaseIII、Dicer、Argonaute、Argonaute2、およびヒト免疫不全ウイルスのトランス活性化応答RNA結合タンパク質(TRBP)からなる群より選択されるタンパク質と結合する、請求項1に記載のナノ粒子組成物。
- 前記二重鎖の前記ドメインの長さが、10ヌクレオチドである、請求項1に記載のナノ粒子組成物。
- 前記二重鎖が、前記標的ポリヌクレオチド内の第2の配列と十分に相補的であり、長さが10〜30ヌクレオチドである第2のドメインをさらに含み、該二重鎖の該第2のドメインと該標的ポリヌクレオチド内の該第2の配列とのハイブリッド形成によって、第2のポリペプチドによって認識される追加の基質部位がもたらされる、請求項10に記載のナノ粒子組成物。
- 前記ポリヌクレオチドの前記第2のドメインの長さが、10ヌクレオチドである、請求項11に記載のナノ粒子組成物。
- 前記基質部位と前記追加の基質部位が同じである、請求項11に記載のナノ粒子組成物。
- 前記RNAポリヌクレオチドの長さが、5から100ヌクレオチドである、請求項1に記載のナノ粒子組成物。
- 前記追加のポリヌクレオチドの長さが、5から100ヌクレオチドである、請求項1に記載のナノ粒子組成物。
- 金ナノ粒子である請求項1に記載のナノ粒子組成物。
- 標的ポリヌクレオチドの発現を調節するための、請求項1に記載のナノ粒子組成物であって、該ナノ粒子組成物のドメインを該標的ポリヌクレオチドとハイブリッド形成させて、ポリペプチドのための基質部位を形成させることを特徴とする、ナノ粒子組成物。
- 前記ナノ粒子組成物の前記ドメインと前記標的ポリヌクレオチドとのハイブリッド形成によって前記標的ポリヌクレオチドの分解をもたらす、請求項17に記載のナノ粒子組成物。
- 前記ポリペプチドが、RNaseH、RNaseD、RNaseL、RNaseIII、Dicer、Argonaute、Argonaute2、およびTRBPからなる群より選択される、請求項17または18に記載のナノ粒子組成物。
- 前記追加のポリヌクレオチドが、長さが18〜21ヌクレオチドである少なくとも1つのドメインを有する、請求項1に記載のナノ粒子組成物。
- 前記第2のドメインは、長さが18〜21ヌクレオチドである、請求項11に記載のナノ粒子組成物。
- 前記ナノ粒子は、少なくとも2つのRNAポリヌクレオチドを含み、前記少なくとも1つの結合した各RNAポリヌクレオチドが、異なる配列を有する点で少なくとも1つの他の結合したRNAポリヌクレオチドと異なる、請求項1に記載のナノ粒子組成物。
- 異なる位置または基質部位で同じポリヌクレオチドを標的にする、あるいは異なる遺伝子産物をコードする異なるポリヌクレオチドと結合する、請求項22に記載のナノ粒子組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11744908P | 2008-11-24 | 2008-11-24 | |
US61/117,449 | 2008-11-24 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015077341A Division JP2015126751A (ja) | 2008-11-24 | 2015-04-06 | 多価rna−ナノ粒子組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017127327A JP2017127327A (ja) | 2017-07-27 |
JP6466500B2 true JP6466500B2 (ja) | 2019-02-06 |
Family
ID=41698439
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011537727A Active JP5749172B2 (ja) | 2008-11-24 | 2009-11-24 | 多価rna−ナノ粒子組成物 |
JP2015077341A Withdrawn JP2015126751A (ja) | 2008-11-24 | 2015-04-06 | 多価rna−ナノ粒子組成物 |
JP2017082667A Active JP6466500B2 (ja) | 2008-11-24 | 2017-04-19 | 多価rna−ナノ粒子組成物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011537727A Active JP5749172B2 (ja) | 2008-11-24 | 2009-11-24 | 多価rna−ナノ粒子組成物 |
JP2015077341A Withdrawn JP2015126751A (ja) | 2008-11-24 | 2015-04-06 | 多価rna−ナノ粒子組成物 |
Country Status (10)
Country | Link |
---|---|
US (3) | US9139827B2 (ja) |
EP (2) | EP2365803B1 (ja) |
JP (3) | JP5749172B2 (ja) |
KR (1) | KR101692880B1 (ja) |
CN (2) | CN102281872A (ja) |
AU (2) | AU2009316286B2 (ja) |
CA (1) | CA2744207C (ja) |
DK (1) | DK2365803T3 (ja) |
MX (1) | MX2011005429A (ja) |
WO (1) | WO2010060110A1 (ja) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
MX2009008470A (es) | 2007-02-09 | 2009-11-26 | Univ Northwestern | Particulas para detectar objetivos intracelulares. |
EP2826863B1 (en) | 2007-05-30 | 2017-08-23 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
MX2010011680A (es) | 2008-04-25 | 2011-05-03 | Univ Northwestern | Nanoestructuras adecuadas para secuestrar colesterol y otras moleculas. |
WO2010060110A1 (en) | 2008-11-24 | 2010-05-27 | Northwestern University | Polyvalent rna-nanoparticle compositions |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
EP2385760A4 (en) * | 2009-01-08 | 2015-09-30 | Univ Northwestern | INHIBITION OF THE PRODUCTION OF BACTERIAL PROTEINS BY POLYVALENT CONJUGATES OF OLIGONUCLEOTIDE MODIFIED NANOPARTICLES |
KR20120136345A (ko) | 2009-10-30 | 2012-12-18 | 노오쓰웨스턴 유니버시티 | 주형화된 나노컨쥬게이트 |
WO2011091065A2 (en) | 2010-01-19 | 2011-07-28 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
CN104024854A (zh) | 2011-09-11 | 2014-09-03 | 奥拉森斯有限责任公司 | 细胞摄取对照*** |
EP2755692B1 (en) | 2011-09-14 | 2020-11-25 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
AU2014292928A1 (en) | 2013-07-25 | 2016-03-03 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunoregulatory agents |
ES2750608T3 (es) | 2013-07-25 | 2020-03-26 | Exicure Inc | Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico |
GB201313897D0 (en) * | 2013-08-02 | 2013-09-18 | Maersk Olie & Gas | Conformance control in enhanced oil recovery |
US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
KR102290205B1 (ko) | 2014-06-04 | 2021-08-20 | 엑시큐어, 인크. | 예방 또는 치료 용도를 위한 리포솜성 구형 핵산에 의한 면역 조절인자의 다가 전달 |
US9910035B1 (en) | 2014-07-16 | 2018-03-06 | Verily Life Sciences Llc | Polyvalent functionalized nanoparticle-based in vivo diagnostic system |
MX2017004448A (es) | 2014-10-06 | 2017-10-23 | Exicure Inc | Compuestos anti-factor de necrosis tumoral (tnf). |
WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US10517924B2 (en) | 2014-11-24 | 2019-12-31 | Northwestern University | High density lipoprotein nanoparticles for inflammation |
US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
US20180208456A1 (en) * | 2015-07-21 | 2018-07-26 | Dnp123 Company | Programmable, self assembling patched nanoparticles, and associated devices, systems and methods |
US10967072B2 (en) | 2016-04-27 | 2021-04-06 | Northwestern University | Short interfering RNA templated lipoprotein particles (siRNA-TLP) |
EP3452598A4 (en) | 2016-05-06 | 2020-04-29 | Exicure, Inc. | LIPOSOMAL SPHERIC NUCLEIC ACID (SNA) CONSTRUCTS WITH ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC KNOCKDOWN OF INTERLEUKIN-17 RECEPTOR MRNA |
CN107435063B (zh) * | 2016-05-27 | 2020-12-22 | 首都师范大学 | 一种快速制备巯基修饰DNA纳米金复合物(DNA-AuNP)的方法 |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
US10973927B2 (en) | 2017-08-28 | 2021-04-13 | The Chinese University Of Hong Kong | Materials and methods for effective in vivo delivery of DNA nanostructures to atherosclerotic plaques |
CN107881176A (zh) * | 2017-11-16 | 2018-04-06 | 苏州纳葛诺斯生物科技有限公司 | 标记外泌体的试剂及其制备方法和使用方法 |
CN109777794A (zh) * | 2019-01-04 | 2019-05-21 | 三峡大学 | 一种核糖核酸酶及其抑制剂筛选的发光体系,制备方法及其应用 |
WO2020181144A1 (en) * | 2019-03-06 | 2020-09-10 | Northwestern University | Hairpin-like oligonucleotide-conjugated spherical nucleic acid |
US20230088835A1 (en) * | 2020-03-02 | 2023-03-23 | Northwestern University | Fit-flares for detection of intracellular analytes in live cells |
JP2023548553A (ja) * | 2020-11-03 | 2023-11-17 | ザ ジェネラル ホスピタル コーポレイション | 治療用放射性標識ナノ粒子およびその使用方法 |
CN114272391B (zh) * | 2021-12-28 | 2023-05-05 | 深圳湾实验室坪山生物医药研发转化中心 | 一种核酸导向的靶rna降解的纳米复合物及其制备方法 |
WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
Family Cites Families (261)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4489055A (en) | 1978-07-19 | 1984-12-18 | N.V. Sopar S.A. | Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
EP0260032B1 (en) | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
US5541308A (en) | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
ATE113059T1 (de) | 1987-06-24 | 1994-11-15 | Florey Howard Inst | Nukleosid-derivate. |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
PT88550A (pt) | 1987-09-21 | 1989-07-31 | Ml Tecnology Ventures Lp | Processo para a preparacao de reagentes de ligacao nao nucleotidicos para sondas nucleotidicas |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
EP0348458B1 (en) | 1987-11-30 | 1997-04-09 | University Of Iowa Research Foundation | Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
JPH03503894A (ja) | 1988-03-25 | 1991-08-29 | ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション | オリゴヌクレオチド n‐アルキルホスホラミデート |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
DK0497875T3 (da) | 1989-10-24 | 2000-07-03 | Gilead Sciences Inc | 2'-modificerede oligonukleotider |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
WO1991013080A1 (en) | 1990-02-20 | 1991-09-05 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
DE69032425T2 (de) | 1990-05-11 | 1998-11-26 | Microprobe Corp., Bothell, Wash. | Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
ATE154246T1 (de) | 1990-07-27 | 1997-06-15 | Isis Pharmaceuticals Inc | Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
HU217036B (hu) | 1990-08-03 | 1999-11-29 | Sanofi | Eljárás génexpresszió gátlására alkalmas vegyületek előállítására |
US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
CA2092002A1 (en) | 1990-09-20 | 1992-03-21 | Mark Matteucci | Modified internucleoside linkages |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
CA2095212A1 (en) | 1990-11-08 | 1992-05-09 | Sudhir Agrawal | Incorporation of multiple reporter groups on synthetic oligonucleotides |
US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US7223833B1 (en) | 1991-05-24 | 2007-05-29 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid conjugates |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
ATE239484T1 (de) | 1991-10-24 | 2003-05-15 | Isis Pharmaceuticals Inc | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
ATE226093T1 (de) | 1991-11-26 | 2002-11-15 | Isis Pharmaceuticals Inc | Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen |
TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US5472881A (en) | 1992-11-12 | 1995-12-05 | University Of Utah Research Foundation | Thiol labeling of DNA for attachment to gold surfaces |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
EP0691968B1 (en) | 1993-03-30 | 1997-07-16 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
WO1994022891A1 (en) | 1993-03-31 | 1994-10-13 | Sterling Winthrop Inc. | Oligonucleotides with amide linkages replacing phosphodiester linkages |
DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
NL9301919A (nl) | 1993-05-27 | 1994-12-16 | Pelt & Hooykaas | Werkwijze voor het afvangen van milieuschadelijke stoffen uit met dergelijke stoffen verontreinigd materiaal. |
ES2186690T3 (es) | 1993-09-02 | 2003-05-16 | Ribozyme Pharm Inc | Acido nucleico enzimatico que contiene no-nucleotidos. |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
DE69415343T2 (de) | 1993-10-27 | 1999-08-26 | Ribozyme Pharmaceuticals | 2'-amido-und 2'-peptido-modifizierte oligonukleotide |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
ATE196311T1 (de) | 1993-12-09 | 2000-09-15 | Univ Jefferson | Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
US5912340A (en) | 1995-10-04 | 1999-06-15 | Epoch Pharmaceuticals, Inc. | Selective binding complementary oligonucleotides |
US20040147022A1 (en) * | 1996-06-06 | 2004-07-29 | Baker Brenda F. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
US20050059016A1 (en) | 2002-11-05 | 2005-03-17 | Ecker David J. | Structural motifs and oligomeric compounds and their use in gene modulation |
US6361944B1 (en) | 1996-07-29 | 2002-03-26 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US20020172953A1 (en) | 1996-07-29 | 2002-11-21 | Mirkin Chad A. | Movement of biomolecule-coated nanoparticles in an electric field |
US6582921B2 (en) | 1996-07-29 | 2003-06-24 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses thereof |
US7098320B1 (en) | 1996-07-29 | 2006-08-29 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6767702B2 (en) | 1996-07-29 | 2004-07-27 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6506564B1 (en) | 1996-07-29 | 2003-01-14 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
EP1818417B1 (en) | 1996-07-29 | 2014-02-12 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6750016B2 (en) | 1996-07-29 | 2004-06-15 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
EP0985033A4 (en) | 1997-04-04 | 2005-07-13 | Biosite Inc | POLYVALENT AND POLYCLONAL LIBRARIES |
US6974669B2 (en) | 2000-03-28 | 2005-12-13 | Nanosphere, Inc. | Bio-barcodes based on oligonucleotide-modified nanoparticles |
WO1999011655A1 (en) | 1997-09-04 | 1999-03-11 | Gryphon Sciences | Modular protein libraries and methods of preparation |
EP2253639A1 (en) | 1997-09-12 | 2010-11-24 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
US6403312B1 (en) | 1998-10-16 | 2002-06-11 | Xencor | Protein design automatic for protein libraries |
US6827979B2 (en) | 1999-01-07 | 2004-12-07 | Northwestern University | Methods utilizing scanning probe microscope tips and products therefor or produced thereby |
AR022404A1 (es) | 1999-01-25 | 2002-09-04 | Photogen Inc | Metodo y agentes para la terapia de radiacion mejorada |
DE60032235T2 (de) | 1999-04-30 | 2007-11-15 | Cyclops Genome Sciences Ltd., West Kirby | Ribonukleinsäurederivate |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
WO2001000876A1 (en) | 1999-06-25 | 2001-01-04 | Mirkin Chad A | Nanoparticles having oligonucleotides attached thereto and uses therefor |
EP1072679A3 (en) | 1999-07-20 | 2002-07-31 | Agilent Technologies, Inc. (a Delaware corporation) | Method of producing nucleic acid molecules with reduced secondary structure |
KR20020064915A (ko) | 1999-11-29 | 2002-08-10 | 에이브이아이 바이오파마 인코포레이티드 | 안티센스 항박테리아 방법 및 조성물 |
US20030181412A1 (en) | 1999-12-21 | 2003-09-25 | Ingeneus Corporation | Method for modifying transcription and/or translation in an organism for therapeutic, prophylactic and/or analytic uses |
WO2001049869A1 (fr) | 1999-12-30 | 2001-07-12 | Aventis Pharma S.A. | Compositions comprenant des acides nucleiques incorpores dans des particules minerales bilamellaires |
US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
JP2004515208A (ja) | 2000-03-28 | 2004-05-27 | ナノスフェアー インコーポレイテッド | オリゴヌクレオチドを付着させたナノ粒子とその使用方法 |
US6991900B2 (en) | 2000-06-28 | 2006-01-31 | California Institute Of Technology | Methods for identifying an essential gene in a prokaryotic microorganism |
CA2415494C (en) | 2000-07-11 | 2007-09-18 | Northwestern University | Method of detection by enhancement of silver staining |
US6806289B1 (en) | 2000-07-14 | 2004-10-19 | Stephen J. Lippard | Coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same |
US6678548B1 (en) | 2000-10-20 | 2004-01-13 | The Trustees Of The University Of Pennsylvania | Unified probabilistic framework for predicting and detecting seizure onsets in the brain and multitherapeutic device |
CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
DE10065475A1 (de) | 2000-12-28 | 2002-07-18 | Switch Biotech Ag | Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion |
US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
IL142875A (en) | 2001-04-30 | 2009-08-03 | Avigdor Shafferman | PEG-linked cholinesterases for the detoxification of circulating organophosphorus |
US20060019917A1 (en) | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
AU2002239726A1 (en) | 2001-05-25 | 2002-12-09 | Northwestern University | Non-alloying core shell nanoparticles |
JP4323949B2 (ja) | 2001-05-30 | 2009-09-02 | ザ・スクリプス・リサーチ・インステイチユート | 核酸用送達系 |
ATE388691T1 (de) * | 2001-07-10 | 2008-03-15 | Univ North Carolina State | Träger zur freisetzung von nanopartikeln |
WO2003046173A1 (fr) | 2001-11-28 | 2003-06-05 | Center For Advanced Science And Technology Incubation, Ltd. | Systeme d'expression d'arn si et procede de production de cellules d'inactivation de genes fonctionnelles et analogues au moyen de ce systeme |
AU2002350332A1 (en) | 2001-12-17 | 2003-06-30 | Tao Chen | Methods of parallel gene cloning and analysis |
US20040038303A1 (en) | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
CA2488048A1 (en) | 2002-05-30 | 2003-12-11 | Memorial Sloan-Kettering Cancer Center | Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
DE10238298A1 (de) | 2002-08-21 | 2004-03-04 | Beiersdorf Ag | Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen |
US20060035344A1 (en) | 2002-10-18 | 2006-02-16 | Pachuk Catherine J | Double-stranded rna structures and constructs, and methods for generating and using the same |
US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
US20060105343A1 (en) | 2003-01-09 | 2006-05-18 | Children's Medical Center Corporation | Methods for diagnosis and prognosis of cancer |
US7138520B2 (en) | 2003-01-13 | 2006-11-21 | Massachusetts Institute Of Technology | Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same |
US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
US20050096263A1 (en) | 2003-10-30 | 2005-05-05 | Keay Susan K. | Novel antiproliferative factor and methods of use |
US20080057128A1 (en) | 2003-07-18 | 2008-03-06 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from |
US7611728B2 (en) | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
PT1667522T (pt) | 2003-09-09 | 2018-03-20 | Geron Corp | Oligonucleótidos modificados por inibição da telomerase |
US8084599B2 (en) * | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
EP1744620A2 (en) | 2004-05-12 | 2007-01-24 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
GB0411537D0 (en) * | 2004-05-24 | 2004-06-23 | Midatech Ltd | Nanoparticles comprising rna ligands |
US20080213177A1 (en) | 2004-05-24 | 2008-09-04 | Thomas William Rademacher | Nanoparticles Comprising Rna Ligands |
US20060008907A1 (en) | 2004-06-09 | 2006-01-12 | The Curators Of The University Of Missouri | Control of gene expression via light activated RNA interference |
WO2006012695A1 (en) | 2004-08-04 | 2006-02-09 | Panvax Limited | An immunogenic composition |
US20060105342A1 (en) * | 2004-08-31 | 2006-05-18 | Mario Villena | Computerized systems for formation and update of databases |
TW200616606A (en) | 2004-10-19 | 2006-06-01 | Schering Ag | Treatment and prevention of multi-drug resistance |
JP2008524202A (ja) | 2004-12-17 | 2008-07-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 分子イメージング及び治療用のターゲティング造影剤又はターゲッティング治療剤 |
JP2008524203A (ja) | 2004-12-17 | 2008-07-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 分子イメージングのためのターゲティング剤 |
EP1674128A1 (en) | 2004-12-22 | 2006-06-28 | Steinbeis-Transferzentrum für Herz-Kreislaufforschung | Magnetic pole matrices useful for tissue engineering and treatment of disease |
WO2006078777A2 (en) | 2005-01-19 | 2006-07-27 | William Marsh Rice University | Method to fabricate inhomogeneous particles |
KR100704011B1 (ko) | 2005-02-16 | 2007-04-04 | 한국과학기술원 | 금속나노입자와 양자점의 fret에 의한 생체분자특이결합 검출 방법 |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
JP2007101498A (ja) | 2005-10-07 | 2007-04-19 | Fujifilm Corp | 蛍光プローブ及び蛍光検出方法 |
US20090221095A1 (en) | 2005-10-13 | 2009-09-03 | Northwestern University | Colorimetric Screening of DNA Binding/Intercalating Agents with Gold Nanoparticle Probes |
FR2892819B1 (fr) | 2005-10-28 | 2008-02-01 | Centre Nat Rech Scient | Nanoparticules a luminescence persistance pour leur utilisation en tant qu'agent de diagnostic destine a l'imagerie optique in vivo |
US20100167051A1 (en) | 2006-03-31 | 2010-07-01 | Goia Dan V | Process for Manufacture of Silver-Based Particles and Electrical Contact Materials |
WO2008030624A2 (en) | 2006-09-08 | 2008-03-13 | The Research Foundation Of State University Of New York | Nanoparticles for two-photon activated photodynamic therapy and imaging |
MX2009008470A (es) | 2007-02-09 | 2009-11-26 | Univ Northwestern | Particulas para detectar objetivos intracelulares. |
JP2010521460A (ja) * | 2007-03-12 | 2010-06-24 | アンティジェン・エクスプレス・インコーポレーテッド | 癌免疫療法におけるIi−RNAi関与Ii抑制 |
US8323694B2 (en) | 2007-05-09 | 2012-12-04 | Nanoprobes, Inc. | Gold nanoparticles for selective IR heating |
WO2008141289A1 (en) * | 2007-05-10 | 2008-11-20 | Northwestern University | Silver nanoparticle binding agent conjugates based on moieties with triple cyclic disulfide anchoring groups |
EP2826863B1 (en) | 2007-05-30 | 2017-08-23 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
WO2009045579A2 (en) | 2007-06-14 | 2009-04-09 | The Regents Of The University Of California | Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics |
US20080317768A1 (en) | 2007-06-21 | 2008-12-25 | Boeing Company | Bioconjugated nanoparticles |
US7632868B2 (en) | 2007-10-31 | 2009-12-15 | Meta Cosmetics, Llc | Prostaglandin analog compositions to treat epithelial-related conditions |
US20090148384A1 (en) | 2007-12-10 | 2009-06-11 | Fischer Katrin | Functionalized, solid polymer nanoparticles comprising epothilones |
WO2009091582A1 (en) | 2008-01-17 | 2009-07-23 | Indigene Pharmaceuticals, Inc. | PRODUCTION OF R-α-LIPOIC ACID BY FERMENTATION USING GENETICALLY ENGINEERED MICROORGANISMS |
WO2009143157A2 (en) | 2008-05-19 | 2009-11-26 | Cornell University | Self-assembly of nanoparticles through nucleic acid engineering |
WO2010060110A1 (en) | 2008-11-24 | 2010-05-27 | Northwestern University | Polyvalent rna-nanoparticle compositions |
WO2010078516A2 (en) | 2009-01-01 | 2010-07-08 | Cornell University | Multifunctional nucleic acid nano-structures |
EP2385760A4 (en) | 2009-01-08 | 2015-09-30 | Univ Northwestern | INHIBITION OF THE PRODUCTION OF BACTERIAL PROTEINS BY POLYVALENT CONJUGATES OF OLIGONUCLEOTIDE MODIFIED NANOPARTICLES |
KR20120022938A (ko) | 2009-04-15 | 2012-03-12 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오티드 관능화된 나노입자의 전달 |
US20120269730A1 (en) | 2009-08-07 | 2012-10-25 | Northwestern University | Intracellular Delivery of Contrast Agents with Functionalized Nanoparticles |
US9307200B2 (en) | 2014-04-10 | 2016-04-05 | Cisco Technology, Inc. | Use of face and motion detection for best view framing in video conference endpoint |
-
2009
- 2009-11-24 WO PCT/US2009/065822 patent/WO2010060110A1/en active Application Filing
- 2009-11-24 JP JP2011537727A patent/JP5749172B2/ja active Active
- 2009-11-24 KR KR1020117014393A patent/KR101692880B1/ko active IP Right Grant
- 2009-11-24 CA CA2744207A patent/CA2744207C/en active Active
- 2009-11-24 AU AU2009316286A patent/AU2009316286B2/en active Active
- 2009-11-24 EP EP09760436.7A patent/EP2365803B1/en active Active
- 2009-11-24 MX MX2011005429A patent/MX2011005429A/es unknown
- 2009-11-24 EP EP17190472.5A patent/EP3335705A1/en not_active Withdrawn
- 2009-11-24 US US12/625,537 patent/US9139827B2/en active Active
- 2009-11-24 CN CN2009801469856A patent/CN102281872A/zh active Pending
- 2009-11-24 DK DK09760436.7T patent/DK2365803T3/en active
- 2009-11-24 CN CN201710191137.3A patent/CN106955360A/zh active Pending
-
2015
- 2015-04-06 JP JP2015077341A patent/JP2015126751A/ja not_active Withdrawn
- 2015-08-26 US US14/836,528 patent/US9844562B2/en active Active
-
2016
- 2016-08-25 AU AU2016219644A patent/AU2016219644B2/en active Active
-
2017
- 2017-04-19 JP JP2017082667A patent/JP6466500B2/ja active Active
- 2017-11-10 US US15/809,464 patent/US10391116B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180085390A1 (en) | 2018-03-29 |
DK2365803T3 (en) | 2018-01-22 |
CA2744207A1 (en) | 2010-05-27 |
KR101692880B1 (ko) | 2017-01-04 |
US10391116B2 (en) | 2019-08-27 |
WO2010060110A1 (en) | 2010-05-27 |
JP5749172B2 (ja) | 2015-07-15 |
US20150352138A1 (en) | 2015-12-10 |
EP2365803A1 (en) | 2011-09-21 |
AU2016219644B2 (en) | 2018-04-05 |
US9139827B2 (en) | 2015-09-22 |
EP3335705A1 (en) | 2018-06-20 |
EP2365803B1 (en) | 2017-11-01 |
JP2015126751A (ja) | 2015-07-09 |
AU2009316286A1 (en) | 2010-05-27 |
JP2017127327A (ja) | 2017-07-27 |
KR20110089433A (ko) | 2011-08-08 |
JP2012509674A (ja) | 2012-04-26 |
MX2011005429A (es) | 2011-06-21 |
AU2016219644A1 (en) | 2016-09-15 |
US20100136682A1 (en) | 2010-06-03 |
AU2009316286B2 (en) | 2016-05-26 |
CN102281872A (zh) | 2011-12-14 |
CN106955360A (zh) | 2017-07-18 |
CA2744207C (en) | 2019-05-28 |
US9844562B2 (en) | 2017-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6466500B2 (ja) | 多価rna−ナノ粒子組成物 | |
US10370656B2 (en) | Nucleic acid functionalized nanoparticles for therapeutic applications | |
US10370661B2 (en) | Nucleic acid functionalized nanoparticles for therapeutic applications | |
AU2014262264B2 (en) | Nucleic Acid Functionalized Nanoparticles For Therapeutic Applications | |
AU2016269532A1 (en) | Nucleic Acid Functionalized Nanoparticles For Therapeutic Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170419 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180717 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181211 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190109 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6466500 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |